AI Regulation Moves Theory to Practice in Life Sciences

Key Takeaways

Current state of AI regulation in life sciences

For the past few years, AI in life sciences meant pilot programs and cautious position papers. That changed fast.

In January 2026, the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) jointly released the Guiding Principles of Good AI Practice in Drug Development, covering the use of AI to generate evidence across the drug lifecycle, from early research through manufacturing and post-market safety monitoring.

FDA has also been building and using its own AI tools internally, including systems for reviewing drug protocols and evaluating medical devices. That internal use does not itself create new obligations for industry.

Anita Modi, CEO and co-founder of Peer AI, offered this commentary in a December 2025 analysis for Pharmaphorum, and it reflects her interpretation rather than an FDA position:

"By adopting AI internally while mandating provenance and traceability, the FDA redefined compliance across drug and device development."

Her forecast for the year: "In 2026, biopharma will move from proving AI works to proving it can be trusted at scale."

The difference between a tool that works and one that is trustworthy and auditable is a theme in this year's regulatory discussion. It is also where infrastructure and documentation gaps tend to surface.

The FDA and EMA guiding principles

The Guiding Principles are meant to inform good practice across the lifecycle of an AI tool, from data governance to model design to ongoing monitoring.

They do not independently impose a new binding compliance regime. The ten principles are:

1. Human-centric design, prioritizing ethical and human-focused values
2. A risk-based approach, with oversight scaled to the risk the AI actually poses
3. Adherence to applicable legal, technical, and regulatory standards
4. A clearly defined context of use for each AI application
5. Multidisciplinary expertise brought into development and review
6. Data governance and documentation that keeps sources and decisions traceable
7. Model design and development practices that support interpretability and explainability, fit-for-use data, predictive performance, robustness, and generalizability
8. Risk-based performance assessment using appropriate metrics
9. Lifecycle management, with ongoing monitoring and periodic reevaluation
10. Clear, accessible communication about what the AI can and can't do

The principles are nonbinding, per Jones Day's analysis of the guidance. Voluntary guidance can still shape what reviewers expect over time, but it does not create a new compliance regime on its own.

Principle six, data governance and documentation, depends heavily on infrastructure controls as well as policies.

A data governance policy is only as strong as the systems that enforce it. If the underlying systems do not control who can access what data, and when, the policy is hard to demonstrate in practice.

EU AI Act deadlines

August 2, 2026 has already come and gone, and if you were bracing for the EU AI Act's high-risk compliance deadline to hit that day, it didn't, because the rules changed underneath it earlier this summer.

Here is what changed. The Council approved the AI Omnibus on June 29, 2026. It was published in the Official Journal on July 24 and entered into force on July 27, 2026. The revised application dates are:

According to Holland & Knight's coverage of the lead-up to this decision, the extension moved through Council agreement, a provisional Parliament-Council agreement, Parliament endorsement, and final Council approval. Council approval and entry into force are separate steps. The amendment entered into force on July 27, 2026, so the delay is now settled law, not a proposal.

Article 50's transparency obligations generally apply from August 2, 2026. One transition applies: providers of synthetic-content systems placed on the market before that date have until December 2, 2026 to meet the machine-readable marking requirement in Article 50(2). Machine-readable marking does not necessarily mean a visible watermark.

The delay for high-risk systems still leaves substantive work in place. Compliance for a high-risk system includes conformity assessment, technical documentation, EU database registration, and automatic event logging. That is not something you stand up in a sprint.

Which life sciences AI systems are high-risk

Working in pharma, biotech, or medtech does not make an AI system high-risk. Classification depends on the system's intended purpose.

Article 6 sets two routes. Under Article 6(1), a system is high-risk when it is a safety component of a product, or is itself a product, covered by the EU product legislation listed in Annex I, and that product requires third-party conformity assessment.

Under Annex III, systems used for specified purposes are high-risk, subject to the exceptions in Article 6(3).

Annex I includes the EU medical device and in vitro diagnostic regulations. The Commission's May 2026 draft classification guidelines read the third-party conformity assessment condition broadly, so medtech teams should review them.

A trial-data summarizer, for example, is not automatically high-risk because a pharmaceutical company uses it. Assess intended purpose against Article 6 and the relevant annexes first. GxP, privacy, and electronic-record requirements may still apply either way.

What Article 14 requires for human oversight

Article 14 of the EU AI Act is where human oversight becomes a design requirement for high-risk AI systems. Those systems must be built so that people can effectively oversee them while in use.

Concretely, the people assigned to oversight need to understand the system's capabilities and limitations, monitor for anomalies and unexpected behavior, stay aware of automation bias, and be able to disregard, override, or reverse an output.

They also need to be able to interrupt the system safely. Article 26(2) adds that deployers must assign oversight to people with the necessary competence, training, and authority.

Infrastructure supports oversight but does not replace it. Server access controls alone are not human oversight.

Still, an override mechanism only works if the right people can reach it, and loose access controls (a service account with more permissions than it needs, a test environment that shares credentials with production) can undermine oversight in practice.

Human oversight, logging, and security are separate requirement areas. Human oversight falls under Article 14, automatic logging is principally addressed in Article 12, and cybersecurity falls under Article 15. Access controls can support all three, but they are not a substitute for any of them.

The infrastructure work here has two layers. The first is the environment itself: appropriate logical or physical separation between development, test, QA, and production, sized to risk and intended use. Neither Article 14 nor the FDA/EMA principles prescribe a single architecture.

Managed Cloud is built around that layer, delivering audit-ready environments instead of retrofitting compliance onto whatever already exists.

Operation AI Guardrail sits on top of that foundation, adding AI-specific access and audit controls. Infrastructure services alone cannot establish model validity, clinical suitability, or complete EU AI Act compliance.

Four infrastructure priorities while deadlines move

The delay does not remove the substantive system and operational requirements that high-risk obligations will bring, and it does not reduce the operational risk of ungoverned AI.

Some of what follows depends on whether the base environment was built and validated correctly, and some depends on whether AI specifically is governed within it.

A few things are worth doing now, either way, regardless of which compliance clock is ticking:

1. Inventory the AI tools in your environment

Shadow AI is any AI tool used without IT's knowledge or approval (a formulation scientist pasting trial data into a public chatbot to summarize it faster).

In a life sciences environment, that means protected health data, unpublished trial results, or manufacturing records leaving a validated system and landing somewhere outside approved governance, with uncertain retention, access, data-use, and audit arrangements.

Shadow AI is also rarely documented anywhere, which makes an inventory the sensible first step.

In Outeredge's analysis of incidents where an AI tool causes real damage, a recurring theme is a boundary nobody set ahead of time.

2. Separate AI access from other systems

Every AI tool, script, or service account should have exactly the access required to do its job, no more. Security teams call this least privilege.

A script built to flag out-of-spec batch records needs read access to those records, not write access to the production database they live in, and no reason at all to reach backup storage.

Segmentation complements least privilege. It limits lateral movement when something goes wrong. Least privilege can also be enforced through identity, application, database, and API permissions, even on a shared network.

If dev, test, QA, and production all share the same network and credentials, though, there is no clean boundary to draw an AI tool's access around. Implement both controls according to risk.

Separation often erodes over time. Service accounts get provisioned once with broad permissions to avoid future support tickets, new use cases get bolted onto old credentials instead of new ones scoped for the job, and nobody circles back later to remove access that's no longer needed.

Over time, a tool built for one narrow task ends up with permissions far wider than that task ever required. That's how a single compromised or misbehaving AI integration ends up with a blast radius covering systems it had no legitimate reason to reach in the first place.

Operation AI Guardrail's access review traces how AI tools and service accounts are granted permissions today, and flags those with more reach than their job requires.

3. Keep records as you go

If a data scientist adjusts a model's training data in March and nobody logs why at the time, reconstructing that decision in September usually means guessing, or piecing together a plausible explanation a regulator has no way to verify.

Contemporaneous records, meaning documentation created at the same time as the event it describes, are a core data-integrity expectation in regulated environments.

For high-risk systems under the EU AI Act, traceability comes from the data-governance (Article 10), technical documentation (Article 11), and record-keeping and logging (Article 12) requirements, not from Article 14. The FDA/EMA principles also stress traceable data governance and documentation.

This idea has a name in regulatory circles: ALCOA+, short for attributable, legible, contemporaneous, original, and accurate, plus complete, consistent, enduring, and available. FDA's own guidance on data integrity addresses drug CGMP data and explicitly describes ALCOA. Other records, including AI-related ones, need to be assessed under the requirements that apply to them.

Outeredge's change control review examines whether AI tools and automation are actually captured inside existing documentation and audit-trail practices, or quietly operating outside them.

4. Review disaster recovery and backup isolation

Ransomware attacks have repeatedly exploited a common weakness: production and backup systems that trust the same credentials or administrative paths, so an attacker who reaches one can reach the other.

Give an AI tool or automation script that same broad access, and the weakness gets rebuilt on purpose. A script managing storage lifecycle that also has permission to reach the backup repository can turn a single bug, or a bad decision inside an autonomous AI agent, into an event that damages production and the recovery path at the same time.

Stronger backup design keeps protected copies behind separate credentials and administration, on separate infrastructure where practical.

It includes immutable or offline copies, protected administration of the backup platform, and restores that have actually been demonstrated. CISA's #StopRansomware Guide recommends offline, encrypted backups and regular testing of restores.

Outeredge's backup isolation review evaluates exposure by tracing backup architecture, storage permissions, and shared dependencies such as identity, administrative accounts, keys, consoles, and deletion rights. It also tests recovery controls, including protected copies and restore testing.

Where to start

Outeredge has spent more than 15 years managing infrastructure for pharmaceutical, biotech, and medical device companies, inside SOC 2 Type II, HIPAA, 21 CFR Part 11, and ITAR-ready environments. Where to start depends on what's already in place.

If your environment isn't fully built out or validated yet, Managed Cloud delivers infrastructure that's purpose-built, validated, and audit-ready from the start, deployed by senior engineers rather than retrofitted for compliance after the fact.

If the environment already exists and the open question is whether AI tools, access, and audit trails would hold up under scrutiny, Operation AI Guardrail is an assessment designed for that question. It reviews environment separation, access permissions, and logging practices, then maps risk-ranked recommendations.

Three steps work for either path:

1. Confirm whether your environment has appropriate separation for its risk and intended use, and whether its validation status is documented.
2. Pull a current list of every AI tool, script, and service account with access to your environment, including the ones nobody formally approved.
3. Talk to us about whichever assessment fits: Managed Cloud for the foundation, Operation AI Guardrail for the AI-specific layer on top of it.

Frequently Asked Questions

About the author

Jim Heisman

Jim Heisman is a seasoned attorney and technology operator who bridges law, regulation, and real-world infrastructure for highly regulated, technology-driven industries.

Read Jim Heisman’s full bio →